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Malaria, caused by protozoan parasites of the genus
Plasmodium, is one of the leading causes of illness and
death worldwide. Its effects are exacerbated by its ability to
modulate immune responses, which not only impairs the
patient’s ability to fight the malarial infection, but can leave
them vulnerable to some secondary infections and reduce
the immune response to certain vaccines. Although this
partial immunosuppression has been recognized for many
years, the underlying mechanisms are not well understood,
and the results of studies in both humans and animals have
sometimes been contradictory. In recent years, attention has
focused on interference of parasites with the myeloid cells
of the immune system, in particular the antigen-pre-
senting dendritic cells that are essential for the initiation of
almost all adaptive immune responses.
One consequence of malarial infection is the production of
the so-called ‘malaria pigment’ from the breakdown of
hemoglobin by the parasite in infected red blood cells.
Malaria pigment is a polymerized form of heme also known
as hemozoin and has long been suspected to affect the func-
tion of myeloid cells. In this issue of Journal of Biology,
Millington and colleagues [1] show how ingestion of
malaria pigment by dendritic cells alters their function over
the course of the infection, with consequences for the adap-
tive immune response to different asexual blood stages of
the parasite. 
Immature phagocytic dendritic cells reside in most tissues
and constantly sample their environment by phagocytosis
and pinocytosis, surveying for invading pathogens [2].
When pathogens enter a tissue or the blood stream, they are
usually first recognized by pattern recognition receptors
(PRRs) on the surface of dendritic cells, which recognize
molecules common to different classes of pathogen.
Binding of pathogens or their products to the PRRs triggers
the migration of the dendritic cell into lymphoid tissues
and its maturation into a powerful antigen-presenting cell
[3]. Activated dendritic cells migrate to a draining lymph
node or to the spleen, where they initiate an adaptive
immune response by presenting pathogen antigens to
T lymphocytes (T cells). As they mature, their phagocytic
activity decreases, but they increase expression of the cell-
surface major histocompatibility complex (MHC) molecules
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© 2006 BioMed Central Ltd that bind processed pathogen-derived peptides and display
them on the dendritic-cell surface. At the same time the
maturing dendritic cell starts to increase the expression of
cell-surface proteins known as co-stimulatory molecules,
which together with MHC-peptide complexes enable den-
dritic cells to activate any T cells that bind to the antigens
displayed on its surface. 
To activate or not to activate? 
As in many other infectious diseases, dendritic-cell function
in Plasmodium infections has been studied extensively in vivo
and in vitro, but results have been contradictory, depending
on the Plasmodium species, the inoculation dose and the
type of dendritic cells [4] under investigation. Mice, in
which most work has been done, are susceptible to infec-
tion with the species Plasmodium chabaudi chabaudi, P. yoeli,
and P. berghei.  A number of studies have shown that den-
dritic cells can mature in response to Plasmodium infection
and induce a powerful T-cell response.  In one example, the
culture of immature bone-marrow-derived dendritic cells
with mouse red blood cells infected with P. chabaudi
chabaudi resulted in limited maturation of the dendritic
cells, which could be enhanced by external maturational
stimuli such as bacterial lipopolysaccharide (LPS), tumor
necrosis factor-α (TNF-α) or CD40 ligand [5,6]. In a differ-
ent study covering the first four days of a P. chabaudi
chabaudi infection, a subset of splenic dendritic cells found
in the marginal zone of the spleen and characterized by the
cell-surface marker protein CD11c were observed to migrate
from the marginal zone into the T-cell rich periarteriolar
sheath, the area in which immune T-cell responses are initi-
ated [7]. These dendritic cells showed enhanced expression
of MHC class II molecules and co-stimulatory molecules
typical of mature dendritic cells.  In yet another study,
splenic CD11c+ dendritic cells isolated at the peak of a
P. yoeli infection were able to activate antigen-specific T cells
and induce secretion by the T cells of the cytokines inter-
leukin 2 (IL-2), interferon-γ (IFN-γ) and TNF-α, a cytokine
profile characteristic of the Th1 class of differentiated
effector T cells [8]. 
In contrast, other studies have reported that dendritic cells
failed to mature when co-cultured with red blood cells
infected with P. chabaudi chabaudi or P. yoeli, even though
the dendritic cells were subsequently capable of inducing
T-cell responses in vivo when transferred into uninfected
mice [9]. In one study, at the peak of blood-stage infection
(the stage at which the parasite infects red blood cells) the
response of CD8+ cytotoxic T cells (the killer subset of T
lymphocytes) to liver-stage parasites was inhibited in vivo,
most probably as a result of cytokines secreted by dendritic
cells [10]. More recently, Wilson and colleagues [11]
showed that inoculation of mice with P. berghei induced a
systemic activation of splenic dendritic cells similar to that
observed after administration of DNA containing unmethy-
lated CpG, which is a ligand for a type of PRR known as
Toll-like receptor 9 (TLR-9).  As with activation by CpG,
however, if another antigen was administered on day 3 or 4
of a P. berghei infection, the dendritic cells proved unable to
cross-present this exogenous antigen and activate CD8+ T
cells. At this stage of infection, the parasite load in the
blood (parasitemia) is still increasing. The defect in antigen
presentation appeared to be due to reduced dendritic-cell
phagocytic activity.
These studies used a wide variety of in vitro cell culture
systems, functional read outs, Plasmodium species and
mouse strains. A general trend emerges, however, suggesting
that there is a dual response of dendritic cells to Plasmodium
blood-stage infection, with an early phase of activation, in
conditions of low parasitemia, and a late phase of func-
tional inhibition, in conditions of high parasitemia.
Nailing the suspect
The study by Millington and colleagues [1] now not only
reconciles the disparate results on dendritic-cell function in
rodent malaria, but also provides novel insights into the
consequences of dendritic-cell modulation in vivo. Their
careful studies demonstrated an unambiguous biphasic
response of dendritic cells to P. chabaudi chabaudi blood-
stage infection in mice in vivo. They began their investiga-
tions with a simple question: at which stage during the
course of a blood-stage infection does suppression of
immune responses occur? To answer this question they
immunized mice with the protein antigen ovalbumin
(OVA) and LPS (which provides a nonspecific stimulus for
an immune response) at different time points during a
P. chabaudi chabaudi infection and monitored the antibody
response to OVA. Only during the late stages of the infec-
tion, when most parasites had been cleared, did the mice
show greatly reduced OVA-specific IgG responses. 
Millington et al. [1] then demonstrated, through a series of
carefully controlled experiments, that hemozoin acts
directly on the dendritic cells and inhibits their maturation
in response to maturational stimuli such as LPS or the cell-
surface protein CD40 ligand (CD40L). Likewise, CD11c+
dendritic cells isolated from the spleens of infected mice
were activated early but not late during infection, and at the
later stage were refractory to subsequent stimulation with
LPS. Inhibition of dendritic-cell maturation during the late
stages of infection had consequences for the initiation of
adaptive immune responses: antigen-specific T cells were
activated by dendritic cells but failed to proliferate and
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not migrate into B-cell follicles in the spleen to provide the
required help to B cells, and so there was also a failure to
mount a specific antibody response (Figure 1).
Hemozoin has long been known to be a potent modifier of
myeloid cells [12]. Hemozoin is released together with
other cell debris when the mature blood-stage forms of the
parasite cause red blood cells to rupture, and it is rapidly
taken up by monocytes (immature precursors of
macrophages and dendritic cells) and dendritic cells.
Hemozoin reacts with membrane phospholipids, generat-
ing hydroxy-polyunsaturated fatty acids that cause mem-
brane peroxidation [13]. Hydroxy-polyunsaturated fatty
acids inhibit monocyte functions such as phagocytosis,
activation by inflammatory cytokines, and generation of
the oxidative burst [14,15]. Hemozoin also inhibits the dif-
ferentiation of human monocytes to dendritic cells and
their maturation [16]. It has been shown to bind to TLR-9
on the myeloid and plasmacytoid subsets of dendritic cells
in rodents, although this observation was not confirmed in
another study [17,18]. However, activation of dendritic
cells via TLR-9 early during infection, but paralysis of den-
dritic cells via ingested hemozoin during the late stage of
infection would agree with the results of Millington et al.
[1]. Thus, hemozoin is directly associated with the alter-
ation of cellular responses observed during acute malaria in
mice and humans.
In humans, modulation of dendritic-cell function might be
caused by adhesion of infected erythrocytes to the adhesive
cell-surface protein CD36 expressed on dendritic cells.
Adhesion of P. falciparum-infected erythrocytes to CD36 is
mediated by the P. falciparum erythrocyte membrane
protein 1 (PfEMP-1). Does the work of Millington et al. [1]
rule out a role for CD36 in the modulation of dendritic-cell
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Figure 1
Biphasic response of dendritic cells to Plasmodium blood-stage infection in rodents. (a) Early on during infection, engagement of TLR-9 by hemozoin
may result in dendritic-cell maturation. Mature dendritic cells present antigen to T cells and induce their activation. Activated T cells proliferate and
migrate into primary B-cell follicles where they provide help for antibody production by B cells. (b) With increasing parasitemia, more and more
myeloid dendritic cells in the spleen are paralyzed through ingestion of increasing amounts of hemozoin, with negative effects on downstream T-cell
and B-cell responses.
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(a) (b)function? PfEMP-1 is not produced by the Plasmodium
species that infect mice [19], and although rodent Plasmod-
ium species can adhere to CD36 to a certain extent, the
ligand (or ligands) mediating CD36 adhesion in rodents are
not known, and expression of adhesion ligand occurs much
later, during the asexual blood-stage phase [20,21]. In addi-
tion, the expression pattern of CD36 on human and mouse
dendritic cells is fundamentally different: only CD8α+ den-
dritic cells in the periarteriolar lymphatic sheath express
CD36 [22,23]. Nevertheless, work by Arese and colleagues
[16] has shown that monocyte function, differentiation to
dendritic cells, and dendritic-cell maturation were impaired
in vitro after ingestion of hemozoin by human monocytes.
Unlike PfEMP-1, hemozoin is present in both human and
rodent Plasmodium species, yet both mechanisms can con-
tribute to the modulation of dendritic-cell function in
humans. 
The seminal in vivo studies presented here in Journal of
Biology by Millington et al. [1] convincingly show that
hemozoin impairs dendritic-cell function in vivo in a rodent
model of malaria, and that it significantly contributes to
immune suppression during acute blood-stage malaria. The
deleterious effects of dendritic-cell paralysis on humans
infected with P. falciparum in endemic malaria areas is easy
to envisage. Many parasite antigens are either clonally
variant or polymorphic. If immune suppression is induced,
adaptive immune responses to variant antigens expressed
during later stages of an infection or to super-infecting
parasites may not be induced efficiently. 
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